Anti cyclin d1 h 295

Manufactured by Santa Cruz Biotechnology

Sourced in China, United States

Anti-Cyclin D1 (H-295) is a primary antibody that specifically recognizes the Cyclin D1 protein. Cyclin D1 is a key regulator of the cell cycle and plays a critical role in the G1/S transition. This antibody can be used for the detection of Cyclin D1 in various applications such as Western blotting, immunoprecipitation, and immunohistochemistry.

Automatically generated - may contain errors

Lab products found in correlation

3 protocols using anti cyclin d1 h 295

Arctiin Inhibits Angiogenic Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols

Arctiin (Purity: 99% by HPLC, Appearance: white crystal power) was manufactured by Chongqing Kerui Pharmaceutical Co., Ltd. (Chongqing, China). Y‐27632 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 3‐(4,5‐methylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) was obtained from Amresco (Solon, Ohio, USA). The following antibodies were used: anti‐PTEN (A2B1, sc‐7974, Santa Cruz, 1:500), anti‐CDK2 (55, sc‐136191, Santa Cruz, 1:500), anti‐CDK4 (3F121, sc‐70831, Santa Cruz, 1:500), anti‐Cyclin D1 (H‐295, sc‐753, Santa Cruz, 1:500), anti‐PI3K (p110α, #4255, Cell Signaling Technology, 1:1000), anti‐Phospho‐PI3K (Tyr458,#4228, Cell Signaling Technology, 1:1000), anti‐Phospho‐Akt (Thr308, #9275, Cell Signaling Technology, 1:500), anti‐Akt (#9272, Cell Signaling Technology, 1:1000), anti‐ROCK1 (EP786Y, ab45171, abcam, 1:1000), anti‐β‐actin (AC‐15,#1978,Sigma,1:50 000), anti‐Ki67 (ab15580, Abcam, 1:1000), Human VEGF PicoKine ELISA Kit (Boster, China) and p‐VEGFR2 (Tyr1175, #2478, Cell Signaling Technology, 1:1000); VEGFR2 (D5B1, #9698S, Cell Signaling Technology, 1:1000).

Zhou M., Li G., Zhu L., Zhou H, & Lu L. (2020). Arctiin attenuates high glucose‐induced human retinal capillary endothelial cell proliferation by regulating ROCK1/PTEN/PI3K/Akt/VEGF pathway in vitro. Journal of Cellular and Molecular Medicine, 24(10), 5695-5706.

+ Open protocol

+ Expand

Cyclin D1 Knockdown Protocols

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cyclin D1-specific siRNA A (siD1-A, 5’-CCAAUAGGUGUAGGAAAUAGCGCTG-3’) was from Integrated DNA Technologies. Cyclin D1-specific siRNA B (siD1-B, 5’-AACACCAGCTCCTGTGCTGCG-3’), C (siD1-C, 5’-GCCCTCGGTGTCCTACTTCAA-3’), control siRNA (AllStars Negative control) were from Qiagen (Valencia, CA, USA). Cyclin D1 shRNA (5’-GCCAGGATGATAAGTTCCTTT-3’), and non-target shRNA (5’-CAACAAGATGAAGAGCACCAA-3’) were from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO, USA). The following antibodies were used: anti-cyclin D1 H295, RAD51 H-92, cyclin A C-19, GST Z-5, CDK2 M-2, CDK4 C-22 antibodies (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), cyclin D3 DCS-22, antibody against the C-terminus of cyclin D1 (Ab3, Thermo Fisher Scientific, Waltham, MA, USA), anti-BRCA2 OP-95 antibody (EMD Millipore), anti-HA 12CA5, CDC25A, γH2AX antibodies (abcam, Cambridge, MA, USA), anti-β actin AKR-002, GAPDH AKR-001antibodies (Sigma-Aldrich). Anti-phospho-Ser3291 BRCA2 antibody was described previously (23 (link)).

Chalermrujinanant C., Michowski W., Sittithumcharee G., Esashi F, & Jirawatnotai S. (2015). Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation. Oncogene, 35(22), 2815-2823.

+ Open protocol

+ Expand

Antibody Validation for Protein Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Anti-LAT1 (#5347), anti-4F2hc (#47213), anti-xCT/SLC7A11 (#12691) and anti-HA (#3724) were purchased from Cell Signaling. Anti-SCRIB (C-20), anti-SCRIB (C-2), anti-LLGL2 antibody (A-4), anti-CD98 (4F2), anti-CD98 (E-5), anti-Erk2 (C-14), and anti-cyclin D1 (H-295) were purchased from Santa Cruz. Anti-HA, anti-CD98hc (BMP090), anti-SLC7A5 (BMP011), and anti-DDDDK-tag (M185) antibodies were purchased from MBL. Anti-SLC7A5 (HPA052673) and anti-SCRIB (HPA023557) antibodies were purchased from ATLAS ANTIBODIES. Anti-Flag antibody (M2) was purchased from Sigma.

Saito Y., Matsuda S., Ohnishi N., Endo K., Ashitani S., Ohishi M., Ueno A., Tomita M., Ueda K., Soga T, & Muthuswamy S.K. (2022). Polarity protein SCRIB interacts with SLC3A2 to regulate proliferation and tamoxifen resistance in ER+ breast cancer. Communications Biology, 5, 403.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!